The latest price target for PTC Therapeutics (NASDAQ:PTCT) was reported by Cantor Fitzgerald on September 17, 2024. The analyst firm set a price target for $64.00 expecting PTCT to rise to within 12 months (a possible 80.38% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for PTC Therapeutics (NASDAQ:PTCT) was provided by Cantor Fitzgerald, and PTC Therapeutics reiterated their overweight rating.

The last upgrade for PTC Therapeutics Inc happened on August 26, 2024 when UBS raised their price target to $47. UBS previously had a neutral for PTC Therapeutics Inc.

The last downgrade for PTC Therapeutics Inc happened on December 19, 2023 when Morgan Stanley changed their price target from N/A to $28 for PTC Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PTC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PTC Therapeutics was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.

While ratings are subjective and will change, the latest PTC Therapeutics (PTCT) rating was a reiterated with a price target of $64.00 to $64.00. The current price PTC Therapeutics (PTCT) is trading at is $35.48, which is out of the analyst’s predicted range.